[ad_1]
This high-dimensional badysis reveals the signature of T cells in people with bowel cancer. The new badysis groups the cells so that all the cells can be viewed at the same time. In the past, cells were considered individually to determine what they were doing. Image credit: University of Otago
Scientists at the University of Otago have discovered a way to visualize the "landscape" immune cells of bowel cancer tumors, paving the way for more individualized medicine and treatment. many other diseases in the future.
In a recently published article on the cover of the Journal of Immunology, scientists have shown the incredible diversity of immune cells inside a colorectal tumor. Immune cells are known to protect against cancer growth and this work provides new insights into the types of cells present and how they might benefit the patient.
Associate Professor Roslyn Kemp, Senior Researcher, explains that she uses a new technology called high-dimensional mbad cytometry to identify cells in tumors of people with bowel cancer.
"You might think you have to take a higher shot of the inside of the tumor. The photo may reveal new cell types that may or may not be targeted by drugs, or reveal a different composition of immune cell populations in individuals that could be used to predict the course of the disease. "
According to badociate professor Kemp, the results of their study showed that the type of immune cells that infiltrate the tumor is extremely diverse, which means that no matter which, or more likely, a combination of many immune cells, could have affect the results for the patient.
The technique could be used to study a number of different diseases, she says.
"This demonstrates the use of a new technology to study the immune response in much more detail than the other methods currently in use, providing new types of information to patients," says Associate Professor Kemp .
"It's a step toward personalized medicine, sometimes called precision medicine, since every patient's tumor could be examined in such detail."
The next step is to conduct a similar study with a slightly different technique to determine if all the cells are in the tumor and how that could affect the functioning of the cells and the relationships between the cell types and the patient's data, such as the stage of the disease and the patient's survival.
The research is funded by the Cancer Research Trust, Lotteries Health Research, the University's School of Biomedical Sciences, along with Associate Professor Kemp, supported by Roche's NZSO Roche Translational Cancer Research Award.
This article has been republished from documents provided by the University of Otago. Note: Content may have changed for length and content. For more information, please contact the cited source.
Reference:
Norton et al. (2019). High-dimensional mbad cytometric badysis reveals an increase in the number of regulator T cells in the effector as a distinctive feature of colorectal tumors. The journal of immunology. 202: 1871-1884
[ad_2]
Source link
